David C. Mamo, MD, MSc, FRCPC | Psychiatrist.com

Original Research

Insight Into Schizophrenia in Earlier and Later Life

April 26, 2017

Over half of patients with schizophrenia experience impaired insight into their illness, which often contributes to negative outcomes. Here, increase your own insight into predicting which of your patients...

Philip Gerretsen, Aristotle N. Voineskos, Ariel Graff-Guerrero, et al

Article

Hyperprolactinemia in Older Patients With Schizophrenia

December 28, 2016

Since older patients are known to be hypersensitive to antipsychotics, are they vulnerable to developing hyperprolactinemia with these drugs? This post hoc study looked at whether the dopamine D2/3...

Yusuke Iwata, Shinichiro Nakajima, Fernando Caravaggio, et al

Original Research

Switching From 2 Antipsychotics to 1 Antipsychotic in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Study

January 27, 2016

Carol Borlido, Gary Remington, Ariel Graff-Guerrero, et al

Original Research

Increased Antipsychotic Sensitivity in Elderly Patients: Evidence and Mechanisms

December 16, 2009

Hiroyuki Uchida, David C. Mamo, Benoit H. Mulsant, et al

Original Research

Monthly Administration of Long-Acting Injectable Risperidone and Striatal Dopamine D2 Receptor Occupancy for the Management of Schizophrenia

August 31, 2008

Hiroyuki Uchida, David C. Mamo, Shitij Kapur, et al

Original Research

Quetiapine Extended-Release Versus Immediate-Release Formulation: A Positron Emission Tomography Study

January 15, 2008

David C. Mamo, Hiroyuki Uchida, Irina Vitcu, et al